OTCKing - Helping tomorrow's FORTUNE 500 companies TODAY!

Aethlon Medical, AEMD, Profile, Summary

Aethlon Medical, AEMD, Profile, Summary


 

Aethlon Medical (AEMD) is developing innovative medical devices to address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Aethlon’s ADAPT™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and Hepatitis C.

 

HER2 Protein and Breast Cancer

Breast cancer is the most common form of cancer in women, accounting for 20% of cancer deaths with approximately 180,000 women diagnosed annually in the United States (Merrill, R. M., and A. Sloan. 2011. Risk-adjusted female breast cancer incidence rates in the United States. Cancer Epidemiol.). Over-expression of the human epidermal growth factor receptor 2 (HER2; ErbB2) gene occurs in approximately 25% of breast cancers and has been linked to poor prognosis (Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182). HER2 is a receptor tyrosine kinase, member of the EGF receptor family, which possesses proliferative and anti-apoptotic activities.

 

The standard of treatment for women diagnosed with HER2+ breast cancer includes the humanized monoclonal antibody trastuzumab (marketed as Herceptin®) directed against the extracellular domain of HER2. Trastuzumab binding to HER2 mediates direct growthinhibition of tumor cells and induces antibody-dependent cell cytotoxicity (ADCC), a major anti-cancer mechanism by which natural killer (NK) cells lyse antibody-coated tumor cells (Nahta, R., D. Yu, M. C. Hung, G. N. Hortobagyi, and F. J. Esteva. 2006. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280).

 

In patients with metastatic breast cancer undergoing chemotherapy, treatment with trastuzumab augments overall response rates and increases median survival time by 25% (Baselga, J. 2001. Clinical trials of Herceptin® (trastuzumab). Eur J Cancer 37 Suppl 1:18-24). However, response rates to trastuzumab range from 12% to 34% with median duration of 9 months due to development of resistance. Despite co-treatment with other HER2 targeting therapies (e.g. the tyrosine kinase inhibitor lapatinib) and chemotherapy, patients with metastatic breast cancer experience a limited duration of benefit; therefore, novel treatment strategies that act synergistically or overcome drug resistance are urgently needed (Sachdev, J. C., and M. Jahanzeb. 2011. Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer.

 

The Evolution of Therapeutic Filtration to Improve Hepatitis-C Virus (HCV) Treatment Outcomes

 

Therapeutic filtration of HCV from the entire circulatory system with a medical device has been clinically demonstrated to improve treatment outcomes when administered at the outset of standard of care (SOC) drug therapy. This summary overview, which includes an introduction to the Aethlon Hemopurifier®, is for informational purposes only.

 

About HCV Infection

The U.S. National Institutes of Health (NIH) reports an estimated 180 million people worldwide are afflicted with chronic HCV infection. Of people infected, 55 to 85% of will develop chronic infection, and 75% of those will develop chronic liver disease. Standard of care (SOC) drug therapy is represented by a two drug combination of interferon and ribavirin. The primary goal of SOC drug therapy is the achievement of a sustained virologic response (SVR), defined as undetectable viral load six months after completion of SOC drug therapy. According to the NIH, 15-25% of HCV infected patients will recover

completely.

 

SOC Drug Therapy Outcomes

The largest study of HCV infected individuals pursuing 48-week SOC drug

therapy was a study of 4,469 genotype 1 patients published by McHutchison in The New England Journal of Medicine in August of 2009.

31% (1,399 of 4,469) of patients screened for participation were excluded from the study.

54% (1,654 of 3,070) of treated patients completed the SOC treatment regimen.

39.6% (1,215 of 3,070) of treated patients who completed SOC therapy

achieved a SVR.

27% (1,215 of 4,469) of the total patients screened for study participation

achieved a SVR.

No data recorded for patients who may have relapsed after achieving a SVR.

 

The Hemopurifier®

The first medical device to selectively remove HCV and related immunosuppressive proteins from circulation. A Study of the Hemopurifier® + SOC Drug Therapy is Now Underway

 

Patient enrollment has been initiated at the Medanta Medicity Institute in India - www.medanta.org

Additional details can be accessed from the Clinical Trials Registry - India (CTRI) link: http://ctri.nic.in/clinicaltrials/index.jsp

Up to 30 patients / up to 6 treatments in first 3 days of SOC

Early clinical endpoints include:

Immediate Virologic Response (IVR)

Rapid Virologic Response (RVR)

Early Virologic Response (EVR)

 

The Hemopurifier® Other Selected Quick Facts

 

70 human treatment experiences administered to date

An Investigation Device Exemption (IDE) to initiate U.S. studies has been filed with FDA

Substantial viral load reductions have also been observed in a human HIV study performed in the absence of antiviral drugs

GMP manufacturing has been established in an FDA approved facility

The Hemopurifier® has proven broad-spectrum capabilities against viral bioterror and pandemic threats

The device has been discovered to capture tumor-secreted exosomes known to suppress the immune system of cancer patients

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

 

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com

ALS, Hepatitis C, Traumatic Brain Injury, Blood Sepsis,breast cancer,HIV,HPV,HCV,SOC, dialysis,DOD,UNT,USPTO, NFL,SOCCOR,MILITARY,COMBAT MISSIONS,PTSD, Ebola


 

 

 

 

Last Updated - Thursday, 26 February 2015
 

Premier Biomedical, BIEI, Profile, Summary

 

Premier Biomedical | BIEI | Profile | Summary

 

Premier Biomedical (BIEI) is a research-based company that has acquired exclusive licenses for patent-pending medications and medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses: ALS, Traumatic Brain Injury, Multiple Sclerosis, Clinical Depression, Alzheimer’s Disease, Blood Sepsis, and Cancer. The company is in the process of developing targeted medicines and procedures and will prove out their superior efficacy in addressing these diseases and others through laboratory, hospital, and actual patient applications. At the anticipated successful conclusion of the clinical trials, contact will be established with the leading worldwide pharmaceutical firms to establish the right to market and distribute Premier Biomedical’s technology products and procedures.
 

INVESTMENT HIGHLIGHTS

· The Company’s proprietary Sequential Dialysis Technique and patented candidate drug Feldetrex are expected to provide superior efficacy versus existing medications in treating a large number of the most fatal diseases

o Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain Injury, Blood Sepsis, and Cancer

 

· The Company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense

o Leverage the substantial infrastructure and resourced capacity of these organizations to perform experimentation and to engage in product development in an inexpensive and efficient manner

o Positive results in animal testing for the Sequential Dialysis Technique treatment of cancer

o Initiation of two clinical trials including a trial for Feldetrex and a trial of the Sequential Dialysis Technique
 

EXECUTIVE SUMMARY

· Premier Biomedical is a research-based company that intends to discover and develop medical treatments targeting the treatment of:  Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain Injury, Blood Sepsis, and Cancer

 

· The Company’s proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects

o Superior to current treatments which eliminate the presence of most illnesses but often with catastrophic or even fatal side effects

o Targets cancer, Alzheimer’s disease, Multiple Sclerosis, ALS, blood sepsis, and Traumatic Brain Injury – collectively over $700 billion market opportunity
 

· Developed a proprietary drug candidate Feldetrex as a potential treatment for Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury

o Expected to deliver significant relief to patients, while presenting fewer side effects than other alternate medications

o The Company was recently granted two US patents for this drug candidate

oThe annual market size of all proposed market segments for Feldetrex is $16 billion
 

· The Company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense

o Leverage the substantial infrastructure and resourced capacity of these organizations to perform experimentation and to engage in product development in an inexpensive and efficient manner

o Positive results in animal testing for the Sequential Dialysis Technique treatment of cancer

o Initiation of two clinical trials including a trial for Feldetrex and a trial of the Sequential Dialysis Technique

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Want to get your company featured? or have questions/comments, please don't hesitate to contact the Editor. editor [@] OTCking.com

Last Updated - Sunday, 02 November 2014
 

Axxess Pharma, AXXE, Profile, Summary

Axxess Pharma, AXXE, Profile, Summary

 

Axxess Pharma (AXXE) is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain as wells as nutritional supplements.

 

Axxess Pharma is dedicated to providing a wide range of products to improve the lives of patients and consumers worldwide.

Axxess Pharma intends to market these products with affordable pricing and widespread availability. The products are targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more. Axxess Pharma will continue to tap the well of innovation to develop ever-more effective and affordable treatment options for the patients.

Axxess Pharma Signed an Exclusive World-Wide License to Market and Sell TapouT Brand Vitamins & Minerals Pain Relief and Muscle Recovery Products. http://shop.tapout.com/

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Want to get your company featured? or have questions/comments, please don't hesitate to contact the Editor. editor [@] OTCking.com

Last Updated - Saturday, 31 January 2015
 

Dalton Industries, DALT, Profile, Summary

Dalton Industries, DALT, Profile, Summary

 

Dalton Industries (DALT) , conducts research and development in the Visual FX, Games and Digital Content Creation industries. Over the years we worked on a variety of feature film, television and game productions creating pipelines, CG art and providing supervision and consultation services in these areas. Dalton aslo makes tools, both hardware and software for users who work in these areas, leveraging their knowledge and experience into commercial products.

Dalton Industries Inc., has been working with various tools and devices related to the Virtual Reality and Augmented Reality industries for the last 2 years.Yet our research efforts go back to the dawn of Virtual Reality in the early 1990s, building our own head mounted displays.

The company is currently working on two software products for commercial release that relate to the Oculus Rift Virtual Reality Head Mounted Display Device and Leap Motion’s Leap Controller for use with content creation packages popular in the Visual FX, Games, 3D Animation and Audio production industries.

Dalton Industries continue to invest in Research and Development with with software products as well, such as the highly acclaimed and heavily used UberCam for LightWave3D. Originally intended exclusively for our own use, UberCam is now one of our most successful tool based products sold through Liberty3d.com. This is a common pattern for us. We build these tools to help us in our work on productions for clients as well as our own projects eventually turning them into commercial products retailed to the industry.

From stereoscopic virtual cameras to character animation and modeling tools in Computer Graphics, our products are being used by artists worldwide. Chances are that if you are a fan of sci-fi and have been watching TV and movies over the last decade you have seen shots that were created using our tools and methodologies.

With the increasing dependence of productions on Visual Effects and Digital Content Creation Tools, Dalton is committed to Research and Development of next generation technology and products in these areas has never been greater.

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Want to get your company featured? or have questions/comments, please don't hesitate to contact the Editor. editor [@] OTCking.com

Last Updated - Saturday, 31 January 2015
 
Page 3 of 58
OTCKing
Sound View Plaza, 7th Floor
1266 E Main St.
Stamford, CT 06902, US
FREE! Premium Membership. DON'T miss the next Exclusive Alert! Become
a MEMBER Today!

Look for exclusive alerts

The Score Card

ARTI.PK* 0.0021   + 52%
EHSK.PK 0.17   + 108%
HGSI 3.35   + 226%
INCC.OB 0.01   + 346%
JGPK.OB 0.18   + 116%
STZU.PK 0.12   + 41%
TTEG.OB 0.36   + 156%

Most Active

Look us up ON
these and other
PREMIER FINANCIALweb sites.
Bloomberg
FREE! Premium Membership. DON'T miss the next Exclusive Alert! Become a MEMBER Today!